The Innovative Drug Research and Bioinformatics Group (IDRB) is a subordinate laboratory of the College of Pharmaceutical Sciences (CPS) in Zhejiang University (ZJU), Hangzhou, China.
IDRB aims at promoting the traditional lock-and-key paradigm in drug development to a more complex network pharmacology, which uses rationally designed synergistic interventions to treat complex and refractory diseases, especially the ones that are yet intractable or poorly managed. Currently, we focus on designing multi-target small molecular drugs for treating cancer, major depression and other sophisticated indications. Moreover, we have started collaboration with renowned synthetic chemists to synthesize computationally verified virtual hits, and are seeking cooperation with biologists to test in-vitro and in-vivo activities.
With the advent of post-genomic era, pharmacogenomics become a new field in pharmacological sciences. In our research, we keep accumulating drug-target information which constantly enriches the current understanding of lock-and-key paradigm. Based on these data, we are developing in-silico technology for indentifying drug targets of diseases such as influenza virus infection, obesity, cancer and so on. Besides, in order to have a more comprehensive understanding of biological networks in disease formation, we are also interested in finding novel protein-protein interactions to construct the whole human interactome.
The permanent lab URLs of IDRB are https://idrblab.org/ (English Version) and https://idrblab.org/CHN.php (Chinese Version). You are very welcome to visit our sites at any time.